Get the DealBook newsletter to make sense of major business and policy headlines — and the power-brokers who shape them. __________Nestlé has struggled to capitalize on its skin care division, but a buyout group might be able to overcome that spotty history. It has been a rocky period: Nestlé underestimated patent expiries and was forced to take a 2.8 billion Swiss franc impairment last year. The skin care unit, which makes a Botox rival called Dysport, could fetch at least 6 billion Swiss francs, or about $6 billion, if it were sold. But selling to another consumer group would be difficult: The business includes both simple over-the-counter and more complex prescription products.

Source: New York Times November 06, 2018 14:41 UTC